We receive funding from a variety of sources that recognize the value of our high-impact research.
Bruce Davidson, PhD
A hexavalent adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment. Bruce Davidson (Co-Principal Investigator). NIH/NIAID. $430,402. 6/1/2024-5/1/2027.
Multivalent QS-18 protein nanoparticles for a broadly protective influenza virus vaccine. Bruce Davidson (Co-Principal Investigator). NIH/NIAID. $199,791. 9/1/2023-9/1/2025.